A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance

Journal of Urology

Volumn 189, Issue 5, 2013, Pages 1930-1938

  Berkers, Joost ^a,b   Govaere, Olivier ^a   Wolter, Pascal ^b   Beuselinck, Benoit ^b   Schöffski, Patrick ^b   Van Kempen, Léon C ^c   Albersen, Maarten ^b   Van Den Oord, Joost ^a,b   Roskams, Tania ^a,b   Swinnen, Johan ^a   Joniau, Steven ^b   Van Poppel, Hendrik ^b   Lerut, Evelyne ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

carcinoma, renal cell; epithelial mesenchymal transition; kidney; MIRN141 microRNA, human; sunitinib

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 144; MICRORNA 155; MICRORNA 376B; MICRORNA 520G; MICRORNA 526B; SUNITINIB; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; KIDNEY METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL HYPOXIA; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INDOLES; KIDNEY NEOPLASMS; MICRORNAS; PYRROLES; TUMOR CELLS, CULTURED;

EID: 84876288448     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.133     Document Type: Article

References (30)

1. W.H. Chow, L.M. Dong, S.S. Devesa Epidemiology and risk factors for kidney cancer Nat Rev Urol 7 2010 245
2. Kidney and Renal Pelvis Cancer - 5-Year Relative Survival Rates, 1975-2004 Bethesda: U.S. National Institutes of Health, National Cancer Institute, Surveillance Epidemiology and End Results http://seer.cancer.gov/ faststats/index.php Accessed January 23, 2013
3. R.C. Flanigan, S.E. Salmon, B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655
4. G.H. Mickisch, A. Garin, H. van Poppel et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966
5. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584
6. R.J. Motzer, J. Bacik, M. Mazumdar Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience Clin Cancer Res 10 2004 6302S
7. B.I. Rini, M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol 10 2009 992
8. D. Huang, Y. Ding, M. Zhou Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res 70 2010 1063
9. E. Huntzinger, E. Izaurralde Gene silencing by microRNAs: contributions of translational repression and mRNA decay Nat Rev Genet 12 2011 99
10. A. Fendler, C. Stephan, G.M. Yousef MicroRNAs as regulators of signal transduction in urological tumors Clin Chem 57 2011 954
11. M.M. Baldewijns, I.J. van Vlodrop, P.B. Vermeulen VHL and HIF signalling in renal cell carcinogenesis J Pathol 221 2010 125
12. Z. Wang, Y. Li, A. Ahmad Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance Drug Resist Updat 13 2010 109
13. E.A. Eisenhauer, P. Therasse, J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228
14. I. Keklikoglou, C. Koerner, C. Schmidt MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways Oncogene 31 2011 4150
15. Z.B. Han, H.Y. Chen, J.W. Fan Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation J Cancer Res Clin Oncol 138 2011 153
16. C. Sangokoya, M.J. Telen, J.T. Chi microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease Blood 116 2010 4338
17. P.A. Gregory, A.G. Bert, E.L. Paterson The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 Nat Cell Biol 10 2008 593
18. S. Brabletz, T. Brabletz The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep 11 2010 670
19. B. Mateescu, L. Batista, M. Cardon miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response Nat Med 17 2011 1627
20. D. Juan, G. Alexe, T. Antes Identification of a microRNA panel for clear-cell kidney cancer Urology 75 2009 835
21. C. Nakada, K. Matsuura, Y. Tsukamoto Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c J Pathol 216 2008 418
22. O. Slaby, J. Jancovicova, R. Lakomy Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy J Exp Clin Cancer Res 29 2010 90
23. Xiong M, Jiang L, Zhou Y, et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol, 302: F369.
24. E. Sanchez-Tillo, L. Siles, O. de Barrios Expanding roles of ZEB factors in tumorigenesis and tumor progression Am J Cancer Res 1 2011 897
25. M. Gerlinger, A.J. Rowan, S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883
26. T. Kunej, I. Godnic, J. Ferdin Epigenetic regulation of microRNAs in cancer: an integrated review of literature Mutat Res 717 2011 77
27. H.J. Hammers, H.M. Verheul, B. Salumbides Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol Cancer Ther 9 2010 1525
28. K.L. Osusky, D.E. Hallahan, A. Fu The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels Angiogenesis 7 2004 225
29. D. Huang, Y. Ding, Y. Li Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma Cancer Res 70 2010 1053
30. S. Loges, M. Mazzone, P. Hohensinner Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 2009 167